Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M

The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency.

As previously reported, before the PRV sale Rocket had cash, cash equivalents and investments of $144.4 million as of March 31, 2026. Following the $180 million in non-dilutive proceeds from the PRV sale, pro forma cash, cash equivalents and investments increased to approximately $322.6 million, which the Company expects to fund operations into the second quarter of 2028.